Their use for Alcohol Use Disorder (AUD) or drug addiction is considered "off-label." However, groundbreaking clinical research from 2025 and 2026 demonstrates that these medications significantly dampen the brain's reward centers, drastically curbing cravings for alcohol, opioids, and nicotine
With continued use, the gastric-emptying effect may diminish somewhat (tachyphylaxis), though other metabolic benefits persist
Ultimately this law exists to benefit patient care, as it provides an option for continuity of care when a patients prescribed medication is in shortage and they cant get it filled at the pharmacy
The glucagon receptor in retatrutide directly stimulates hepatic fat oxidation, creating a specific mechanism for liver fat reduction that dual agonists lack
Document symptom frequency, stool consistency, and any dietary or timing factors that improve or worsen symptoms, then share this information with your healthcare team
S2CID 210954338.